VIRTUAL **26 MARZO 2021**

Perspectives on Oligometastatic and Oligoprogressive Prostate Cancer



S. Arcangeli




VIRTUAL 26 MARZO 2021

Disclosures

- Janssen Cilag (honoraria, advisory board, speaker)
- Astellas Pharma (honoraria, advisory board, speaker)
- **IPSEN** (honoraria, advisory board)

VIRTUAL 26 MARZO 2021







VIRTUAL 26 MARZO 2021



Lesion Uncontrolled





Oligorecurrent or Metachronous primary previously treated Oligoprogressive CSPC or CRPC induced by prior systemic therapy

mCSPC with OS as Primary Endpoint

Study; Total No. (enrollment period)	Experimental Treatment Arm	Survival
GETUG-AFU15 ¹ ; 385 (Oct 2004 to Dec 2008)	Docetaxel	0.88 (0.68-1.14); P = .3
CHAARTED ³ ;790 (July 2006 to July 2012)	Docetaxel	0.72 (0.59-2) = P = .001
STAMPEDE-C ³ ; 1,817 (Oct 2005 to Mar 2013)	Docetaxel	P = .005
(July 2006 to July 2012) STAMPEDE-C ³ ; 1,817 (Oct 2005 to Mar 2013) STAMPEDE-A ⁴ ; 1,002 (Nov 2011 to Jan 2014) LATITUDE ⁵ ; 1,197 (Feb 20) ENZAM (Mar TITAN ⁷ ; July 2) PRACTICE	hangir	ng triais P< .001
(Feb 20)	Chano	J.66 (0.5678); P < .0001
(Mar practic	Jutamide	0.67 (0.52 - 0.86); P = .002
TITAN ⁷ ; PLOC	Apalutamide	0.67 (0.51-0.89); <i>P</i> = .005



The benefit of the combination of DOC or ARTA is uncertain

- in patients with low volume disease* (GETUG-AFU15 and CHAARTED trials)
- in older patients* (≥ 70-75 yrs): in the STAMPEDE, ENZAMET, LATITUDE, and TITAN trials

*the 95% CI for the OS HRs crossed 1

Evidences supporting the role of local treatment in mCSPC

VIRTUAL 26 MARZO 2021

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial



Low burden High burden ... SOC+RT 2.4 SOC 6.4 6.4 SOC+R ort = SOC+RT by Kaplan Heler to a SOCHET by Kasher Mar ---- SOC by facible parametric mode ----- SOC by facible parametric mode SOC+RT by facilitie parametric mo 24 24 30 SOC SOC+RT 43 (41) 312 HR: 1.07 (95% CI 0.90-1.28); p=0.420 HR: 0.68 (95% CI 0.52-0.90); p=0.007 3 year OS (%): SOC = 73% 3 year OS (%): SOC = 54% SOC+RT = 53% SOC+RT = 81%


Overall survival: metastatic burden subgroup analysis

VIRTUAL 26 MARZO 2021

℈@**ݨ**⋒

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

А	Control	Radiotherapy	Interaction p value	HR (95% CI)
	Deaths/N	Deaths/N		
Metastatic bure	den			
Low burden	116/409	90/410	0.0098	0.68 (0.52–0.90)
High burden	252/567	257/553	•	1.07 (0.90–1.28)
Radiotherapy s	chedule			
Weekly	179/482	182/497	0.27 •	1.01 (0.82–1.25)
Daily	212/547	188/535	•	0.86 (0.71–1.05)
			0.5 0.6 0.7 0.8 0.9 1.0 1.2	1.4
			Favours radiotherapy Favours control	ol




Oligometastatic state and "Disease Burden"

- **"Low-volume"** (CHAARTED)
- Exclusion: Either of the following: (a) ≥4 bone mets on bone scan, with ≥1 outside the vertebral bodies or pelvis or (b) visceral mets
- **"Low-risk"** (LATITUDE)
- Exclusion: Any two of the following: (a) ≥3 bone mets on bone scan,
 (b) Gleason score ≥8, or (c) Visceral mets

Kyriakopolous et al. JCO 2018 Hoyle et al. Eur Urol 2019

Is Low Volume/Low Risk = Oligometastatic?


...NO !



JAMA Oncology | Original Investigation


Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer

A Secondary Analysis of a Randomized Clinical Trial





Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial



New Metastatic Burden Classification (with Conventional Imaging)

• Low-burden

 – NRLN or ≤ 3 or fewer bone metastases ± NRLN regardless of axial or extra axial location and without any visceral metastasis

- High-burden
 - All the others

Ali et al. JAMA Oncology 2021


Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial

STUDY PROTOCOL



VIRTUAL 26 MARZO 2021

David A Palma^{1*}, Cornelis J A Haasbeek², George B Rodrigues¹, Max Dahele², Michael Lock¹, Brian Yaremko¹, Robert Olson³, Mitchell Liu³, Jason Panarotto⁴, Gwendolyn H M J Griffioen², Stewart Gaede¹, Ben Slotman² and Suresh Senan²



INCLUSION CRITERIA:

- Controlled primary tumor
- Up to 3 mts in any organ/system
- Total number of mts < 5
- life expectancy > 6 months
- No CT 4 weeks prior, during or 2 weeks after RT


20% prostate cancer patients

Baseline Patient Characteristics

<u>Characteristic</u>	<u>All Patients</u> (n=99)	<u>Control Arm</u> (n=33)	<u>SABR Arm</u> (n=66)	<u>p-value</u>
Number of Metastases – n(%)				0.591
1	42 (42.4)	12 (36.4)	30 (45.5)	
2	32 (32.3)	13 (39.4)	19 (28.8)	
3	18 (18.2)	6 (18.2)	12 (18.2)	
4	4 (4.0)	2 (6.1)	2 (3.0)	
5	3 (3.0)	0 (0.0)	3 (4.6)	
Location of Metastases – n(%)				0.181
Adrenal	9 (4.7)	2 (3.1)	7 (5.5)	
Bone	65 (34.0)	20 (31.3)	45 (35.4)	
Liver	19 (10.0)	3 (4.7)	16 (12.6)	
Lung	89 <mark>(</mark> 46.6)	34 (53.1)	55 (43.3)	
Other	9 (4.7)	5 (7.8)	4 (3.2)	

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

Median follow up: 51 months




VIRTUAL 26 MARZO 2021



RT and abiraterone together ?
 No concerning safety interaction from the STAMPEDE

Any benefit in treating metastatic sites ?
 The next arm of STAMPEDE (arm M) randomizes
 patients to systemic therapy and RT to the primary ±
 metastasis-directed therapy

VIRTUAL 26 MARZO 2021



 The benefit of the combination of DOC or ARTA is uncertain in the subset of men developing metastatic disease after initial local treatment*

*the 95% CI for the OS HRs crossed 1(GETUG-AFU15, CHAARTED and ENZAMET)

75% of patients with recurrence after primary therapy have ≤3 involved sites*

*Singh D, et al. Int J Radiat Oncol Biol Phys. 2004;58:3-10. Schweizer MT,et al. Ann Oncol. 2013;24:2881-2886. Sridharan S, et al. Radiother Oncol. 2016;121:98-102. De Bruycker A, et al. BJU Int. 2017;120:815-821.

What are the data supporting ablative therapy in mCSPC?




Study	Study Design	Sample size	Follow-up	Intervention	Control	Outcome measure
Kneebone et al (2018) [10]	Single-arm, prospective observational study	57 patients	16.0 (range: 5.0-31.0) mo	Median b-PFS: 11.0 mo (95% Cl, 8.1-13.9)	NA	NA
PMID: 31158100	SBRT			I-PFS: 100%		
Bowden et al (2020) [13]	Single-arm, prospective observational study, interim results	199 patients, 176 patients available at last FUP	35.1 (range: 6.5–51.3) mo, including patients lost to FUP	b-PFS: 41/176 (23.3%) at last FUP	NA	NA
PMID: 31199504	SBRT					
Muacevic et al (2013) [17]	Single-arm, prospective observational study	40 patients	10.2 (range: 3.0–48.0) mo	I-PFS:	NA	NA
PMID: 21481619	SRS			At 6 mo: 95,5% (95% Cl, 83.0–98.8) At 12 mo: 95,5% (95%		
				Cl, 83.0–98.8) At 24 mo: 95.5% (95% Cl, 83.0–98.8)		
Siva et al (2018) [11]	Single-arm, prospective observational study	33 patients	24,0 mo	I-PFS:	NA	NA
PMID: 30227924	SABR			At 12 mo: 97.0% (95% Cl. 91.0-100.0)		
				At 24 mo: 93.0% (95% Cl. 84.0-100.0)		
Ost et al (2018) [3]	Randomized (1:1), prospective	31 patients in both the intervention and the control group (<i>n</i> =62)	36 (IQR: 27.6–45.6) mo	Median b-PFS: 10.0 (80% Cl, 8.0–13.0) mo	Median b-PFS: 6.0 (80% CI, 4.0-7.0) mo	b-PFS: HR, 0.53; 80% CI, 0.37–077 p=0.03
PMID: 29240541	MDT vs observation, interim results			I-PFS: 100%	l-PFS: 80.6% (no. of events=6)	l-PFS: not provided
Phillips et al (2020) [16]	Randomized (2:1), prospective	36 patients in the intervention group and 18 in the control group (n= 54)	18.8 (range: 5.8–35.0) mo	Median b-PFS not reached	Median b-PFS: 6.4 mo	b-PFS: HR, 0.31; 95% CI, 0.13–0.75 p=0.002
PMID: 32215577	SBRT vs observation, interim results			b-PFS at 6 mo: 4 events/36, 11%; 95% Cl, 3.9-26.1	b-PFS at 6 mo: 9 events/18, 50%; 95% CI, 29,1-70,9	b-PFS at 6 mo: p=0.005
				I-PFS at 6 mo: 98.9% (1 event)	1-PFS: not provided	l-PFS: not provided

STUDY PROTOCOL

Open Access


Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial

Karel Decaestecker¹, Gert De Meerleer², Filip Ameye³, Valerie Fonteyne², Bieke Lambert⁴, Steven Joniau⁵, Louke Delrue⁶, Ignace Billiet⁷, Wim Duthoy⁸, Sarah Junius⁹, Wouter Huysse⁶, Nicolaas Lumen¹ and Piet Ost^{2*}



Reasons to start ADT: local progression, symptomatic progression or polymetastatic progression

VIRTUAL 26 MARZO 2021




Ost et al. JCO 2018

Indication	Surveillance (n = 31)	gen Deprivation Therapy Metastasis-Directed Therapy (n = 31)		
Not started yet	6 (19)	12 (39)		
Polymetastatic progression	16 (55)	19 (61)		
Local progression	6 (23)	0 (0)		
Symptomatic progression	3 (10)*	O (O)		
NOTE. Data are presented as No. (%). *Two patients with symptomatic progression also showed local and poly- metastatic progression.				

Ost et al. JCO 2018


JAMA Oncology | Original Investigation

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer The ORIOLE Phase 2 Randomized Clinical Trial



FINDINGS

Progression of disease at 6 mo was less common with SABR compared with observation (19% vs 61%; P=.005)




Proportion of patients with progression at 6 mo Stereotactic radiotherapy: **19%** Observation: **61%**


С

PSMA-targeted PET-CT after randomization

PFS stratified by presence of untreated lesions 100 Progression -free survival, % 80 60 No untreated lesions 40-Any untreated lesions 20 HR, 0.26; 95% CI, 0.09-0.76; P = .006 0-Ó 12 18 24 Time from randomization, mo


45% had lesions not included in RT fields






Phillips et al. JAMA 2020

VIRTUAL 26 MARZO 2021




Potential Effect of Locally Ablative Therapy





"Gotta Catch 'em All", or Do We? *Pokemet* Approach to Metastatic Prostate Cancer



PSMA DETECTION

Number of cells versus volume calculation

Assuming pure cancer cells (which we know is not true)

4/3 π r ³

one cell - 10 um³ = volume = 500 um³

1 mm tumor = 1000 um = 2093 um³ / 500 = 1 million cells

2 mm tumor = 2000 um = volume = 4,000,000,000 um³ /500 = 8 million cells


3 mm tumor = 3000 um = volume = 13,500,000,000 um³ / 500 = 27 million cells

10mm tumor = 10000 um = volume = 50000000000 um³ / 500 = 1,000,000,000 = 1 billion cells

PSA value	PSMA results
0.2-0.49 ng/mL	30% Positive/70% Negative
0.5-0.99 ng/mL	60% Positive/40% Negative
1.0-3.9 ng/mL	80% Positive/20% Negative
> 4 ng/mL	90% Positive/10% Negative

Courtesy Dr. K. Pienta

VIRTUAL 26 MARZO 2021



AUA/ASTRO/SUO Guideline

In progression during AD ADVANCED PROSTATE CANCER: AUA/ASTRO/SUO GUIDELINE


Treatment

27. In newly diagnosed mCRPC patients, clinicians should offer continued ADT with abiraterone acetate plus prednisone, docetaxel, or enzalutamide. (Strong Recommendation; Evidence Level: Grade A [abiraterone acetate plus prednisone and enzalutamide]/B [docetaxel])




Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?

Fabian Lohaus^{a,b,c}, Klaus Zöphel^{c,e}, Steffen Löck^{b,c,a}, Manfred Wirth^{g,h}, Jörg Kotzerke^{c,e}, Mechthild Krause^{a,b,c,f,h}, Michael Baumann^{a,b,d,f,h}, Esther G.C. Troost^{a,b,c,f,h}, Tobias Hölscher^{a,b,*}




Which patients could benefit adding RT to ADT?



Smith MR et al. J Clin Oncol 2013;31:3800-06

How long SBRT is repeatable with the aim of delaying systemic therapy ?



Ryan CJ et al, Lancet Oncol 2015 Beer TM et al, Eur Urol 2017

How long SBRT is repeatable with the aim of delaying systemic therapy ?

CT and Bone scan negative, **PET-CT positive**

	SPARTAN	PROSPER	ARAMIS
MFS - Experimental arm	40.5 mos	36.6 mos	40.4 mos
MFS – Placebo	16.2 mos	14.7 mos	18.4 mos

More than **one year** between each treatment


Smith MR et al, NEJM 2018 Hussain M et al, NEJM 2018 Fizazi K et al. NEJM 2019



Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Statement 3.1

In an asymptomatic or minimally symptomatic oligometastatic mCRPC patient, with a PSA doubling time > 6 months, time to castration resistant phenotype > 12 months, oligometastasis detected by metabolic imaging, radiotherapy with radical intent to metastatic sites could be offered as alternative to androgen receptor target agent to differ systemic treatment



D'Angelillo et al. CROH 2019

VIRTUAL 26 MARZO 2021

In progression during DOC or ARTA New Opportunities in mCRPC

Precision Medicine: PARPi

• Theragnostics: ¹⁷⁷Lu-PSMA-617

VOLUME 34 · NUMBER 12 · APRIL 20, 2016

JOURNAL OF CLINICAL ONCOLOGY


SPECIAL ARTICLE

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

RECOMMENDATION FROM THE PROSTATE CANCER CLINICAL WORKING GROUP 3 (2016):

In cases in which multiple sites of disease continue to respond but one to two sites grow, focal therapy such as radiation or surgery could be administered to the resistant site(s) and systemic therapy continued.

VIRTUAL 26 MARZO 2021



median NEST-free survival of 16 mo

Berghen et al. Eur Urol. 2019

MDT


+ No - Yes

20

Months



Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer



Deek et al. Eur Urol Oncol 2020

40

Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study

Luca Triggiani¹ · Rosario Mazzola² · Stefano Maria Magrini¹ · Gianluca Ingrosso³ · Paolo Borghetti¹ · Fabio Trippa⁴ · Andrea Lancia³ · Beatrice Detti⁵ · Giulio Francolini⁵ · Fabio Matrone⁶ · Roberto Bortolus⁶ · Giuseppe Fanetti⁶ · Ernesto Maranzano⁴ · Francesco Pasqualetti⁹ · Fabiola Paiar⁹ · Marco Lorenzo Bonù¹ · Alessandro Magli¹⁰ · Alessio Bruni¹¹ · Ercole Mazzeo¹¹ · Ciro Franzese¹² · Marta Scorsetti^{12,14} · Filippo Alongi^{1,2} Barbara Alicja Jereczek-Fossa^{7,8} · Piet Ost¹³ · Michela Buglione¹

RESEARCH

Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abirateroneenzalutamide treatment: a monoinstitutional experience

Maurizio Valeriani^{1*}, Luca Marinelli¹, Serena Macrini², Chiara Reverberi¹, Anna Maria Aschelter², Vitaliana De Sanctis¹, Paolo Marchetti², Lidia Tronnolone¹ and Mattia Falchetto Osti¹

Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy

G. Ingrosso¹ · B. Detti² · A. Fodor³ · S. Caini⁴ · S. Borghesi⁵ · L. Triggiani⁶ · F. Trippa⁷ · D. Russo⁸ · A. Bruni⁹ · G. Francolini² · A. Lancia¹⁰ · L. Marinelli¹¹ · N. Di Muzio³ · L. Livi² · S. M. Magrini⁶ · E. Maranzano⁷ · D. Musio⁸ · C. Aristei¹ · M. Valeriani¹¹



World Journal of Urology 2019

Radiation Oncology

(2019) 14:205

Open Access



VIRTUAL 26 MARZO 2021

> Berghen et al. BMC Cancer (2020) 20:457 https://doi.org/10.1186/s12885-020-06853-x

STUDY PROTOCOL

Metastasis-directed therapy in castrationrefractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

Charlien Berghen^{1*}, Steven Joniau², Kato Rans¹, Gaëtan Devos², Kenneth Poels¹, Koen Slabbaert³, Herlinde Dumez⁴, Maarten Albersen², Karolien Goffin⁵, Karin Haustermans¹ and Gert De Meerleer¹

Primary endpoint: postponement of the start of next-line systemic treatment (NEST)



Open Access

BMC Cancer



Open Issues in Oligometastatic Disease

 Does MTD impact clinical outcomes in both synchronous and metachronous or progressive disease ?

✓ What are valid(ated) endpoints?

- Survival
- Time to polymetastatic progression
- Time to systemic therapy

Variable Definitions of Oligometastatic Disease in Representative Trials

TABLE 1. Definition of Oligometastatic Disease and Imaging Modalities Used in Representative Studies of Oligometastatic Prostate Cancer

Study	Туре	Sample Size, No.	Cutoff for Oligometastases, No.	Location of Metastases	Imaging Modality
Singh et al ⁵	R; NA	369	≤5	Any	⁹⁹ "Tc bone scan
Berkovic et al ¹⁴	P; SA	24	≤3	Bone or LN	^{99m} Tc bone scan, ¹ⁿ F-FDG PET/CT, ¹¹ C-choline PET/CT
Schick et al ¹⁸	P; SA	50	≤ 4	NR	^{sem} Tc bone scan, ¹⁸ F-choline PET/CT, ¹¹ C-acetate PET/CT
Decaestecker et al16	P; SA	50	≤3	Bone or LN	^{INF-FDG PET/CT, ^{INF-choline PET/CT}}
Jereczek-Fossa et al ¹⁷	P; SA	69	≤ 1	LN	¹⁰ F-FDG PET/CT, ¹¹ C-choline PET/CT, CT
Ost et al ¹⁸	P; SA	119	≤3	Any	¹⁰ F-FDG PET/CT, ¹⁰ F-choline PET/CT
Ost et al ¹⁹	P; RA	62	≤3	Any	¹⁰ F-choline PET/CT

Abbreviations: FDG, 18-fluorodeoxyglucose; LN, lymph node; NA, not applicable; NR, not reported; P, prospective; R, retrospective; RA, randomized; SA, single arm.

Oligometastatic Prostate Cancer: Future Perspectives

Integration of clinical and molecular features

